Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Klinic vs Zealthy

Klinic
Graded #313

Higher grade

vs+14.099999999999994
Zealthy
Graded #496

Lower grade

The verdict

Klinic takes it — 60.8/100 to 46.7/100.

Klinic grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Klinic is a LegitScript-certified multi-condition telehealth platform prescribing brand-name GLP-1 medications—Wegovy (semaglutide) and Zepbound (tirzepatide)—to patients across all 50 U.S.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKlinic +19
45
26
Dose & formulationZealthy +11
53
64
Clinical oversightKlinic +38
79
41
Labs & monitoringKlinic +11
64
53
FulfillmentKlinic +10
76
66
Contract termsKlinic +14
55
41
Klinic · left barZealthy · right bar

The numbers

MetricKlinicZealthy
WeighScore60.8/10046.7/100
GradeCC
Scorecard rank#313#496
SemaglutideNot disclosed$286/mo (starting dose, plus a separate fee, compounded)
TirzepatideNot disclosed$351/mo (starting dose, plus a separate fee, compounded)
CoverageCoverage not published34 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Klinic

Graded #313 · C

Strengths

  • LegitScript certified, licensed in all 50 states, DEA registered, HIPAA/SOC 2 Type II compliant
  • Broad insurance acceptance including Medicare, Medicaid, BCBS, Aetna, Cigna, UHC, and Humana
  • Klinic handles all prior authorization—patient never manages PA paperwork
  • Brand-name FDA-approved GLP-1s (Wegovy, Zepbound) at full clinical doses with home delivery
  • Named clinical leadership (CMO Dr. Saba Haq, Chief Physician Dr. Vivek Chander) and disclosed founder

Where it loses points

  • Brand-name meds are costly self-pay: Wegovy ~$499/month, Zepbound ~$299/month (med cost alone; consult extra)
  • No compounded semaglutide or tirzepatide option for patients seeking lower-cost alternatives
  • Medication cost is separate from visit fees ($99 initial, $75 follow-up) — total self-pay cost is higher
  • No labs or dedicated nutrition/coaching program included in any plan
  • Pharmacy fulfillment via Klinic Pharmacy Hub Services LLC (non-dispensing hub); actual dispensing is third-party
Zealthy

Graded #496 · C

Strengths

  • Serves 34 states — meaningful nationwide footprint
  • Asynchronous model removes friction for patients who don't want a video visit
  • Independent licensed prescribers retain full clinical authority

Where it loses points

  • Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
  • Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
  • Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
  • Recently rebranded to Gronk Inc. amid active enforcement
  • FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard